and performed an acute, intense exercise protocol (four sets of up to 10 repetitions of the squat, dead lift, and split squat). Participants also performed four sets of up to 10 repetitions of the squat at 24 and 48 h following the initial exercise bout. Blood was sampled before exercise (PRE), immediately postexercise (IP), and 30 min, 24 h, and 48 h postexercise (30P, 24P, and 48P, respectively). Circulating TNF-␣ was assayed, and TNFR1 expression on CD14ϩ monocytes was measured by flow cytometry. The exercise protocol significantly elevated TNF-␣ in only PL (P ϭ 0.006) and CWI (P ϭ 0.045) IP. Mean percent changes show that TNF-␣ significantly increased from PRE to IP for only PL and CWI groups (P Ͻ 0.05), whereas the percent change of TNF-␣ for HMB-FA and HMB-FA-CWI was not significant. TNFR1 expression was elevated in PL (P ϭ 0.023) and CWI (P ϭ 0.02) at 30P compared with PRE, whereas both HMB-FA-treated groups did not increase significantly. In conclusion, HMB-FA attenuated circulating TNF-␣ IP and TNFR1 expression during recovery compared with PL and CWI. HMB-FA supplementation may attenuate the initial immune response to intense exercise, which may reduce recovery time following intense exercise.
muscle damage; immune function; protein; supplement; recovery EXERCISE-INDUCED MUSCLE DAMAGE initiates a series of inflammatory responses to facilitate muscle repair (37, 60) . During the process, potent proinflammatory cytokines, such as TNF-␣, are released by circulating monocytes and macrophages that infiltrate the site of muscle damage (14, 36) . TNF-␣ is involved in signaling the migration of neutrophils and macrophages to the site of muscle damage to initiate the breakdown of tissue (38) . Upon neutrophil release of inflammatory cytokines (IL-1, IL-6) and reactive oxygen species, significant cell breakdown occurs, resulting in muscle-contractile dysfunction, increased catabolism, and decreased myogenesis (7, 8, 31) . Additionally, TNF-␣ is known to be involved in mediating the initial decline in contractile performance following exercise-induced muscle damage (31) .
Nutritional interventions have been used in an attempt to curb the effects of TNF-␣ on muscle damage. Of such interventions, supplementation with ␤-hydroxy-␤-methylbutyrate (HMB), a metabolite of the amino acid leucine, has previously been reported to facilitate recovery and reduce indices of muscle damage with chronic and acute supplementation in young individuals (35, 51, 56, 57) . Supplementation with HMB following exercise-induced muscle damage has been shown to reduce serum creatine kinase (CK) and 3-methylhistidine concentrations in conjunction with an increase in perceived recovery (43, 59) . HMB is also believed to play a role mechanistically in attenuating protein degradation through multiple signaling pathways (11) .
To date, a majority of studies has used a commercially available calcium salt form of HMB (HMB-Ca) (17, 33, 35, 51, 56) . However, HMB-Ca supplementation takes 1-2 h to reach peak plasma concentrations, which may limit its benefits following acute ingestion (58) . Recently, a new free-acid form of HMB (HMB-FA) has been shown to have a more rapid and higher bioavailability compared with HMB-Ca, reaching a greater peak plasma concentration in 36 min (vs. 131 min HMB-Ca) (16) . In addition, HMB-FA supplementation yields a higher plasma clearance level compared with HMB-Ca, indicating greater use by the tissues (16) . These data suggest that acute supplementation with HMB-FA may be more effective than HMB-Ca at attenuating muscle damage and performance decrements following an intense, high-volume, resistance-training protocol (16, 59) . This may potentially allow the athlete a shorter recovery time and an increase in performance in subsequent exercise bouts.
Cold-water immersion (CWI) is another modality commonly used to facilitate muscle repair and recovery (30, 42, 55 ). An earlier study has shown its efficacy in reducing delayed-onset muscle soreness (DOMS) and plasma CK following a DOMS-inducing leg-press protocol (55). Furthermore, CWI has been shown previously to decrease total leukocyte count and attenuate proinflammatory cytokine release following exercise-induced muscle damage (40) . However, little is known about how CWI may modulate TNF-␣-mediated responses to muscle damage models. It is plausible that when used in combination with a nutritional intervention, CWI may mitigate proinflammatory responses and thus reduce muscular damage.
Examination of the presence of TNF-␣ receptors (TNFRs) on specific immune cells and concurrent serum concentrations of these hormones and cytokines may provide further insight to the processes and mechanisms of exercise-induced muscle damage and subsequent repair. Furthermore, the evaluation of how specific modalities may mediate the inflammatory response may provide strategies for improved recovery and subsequent performance. The evaluation of receptors on circulating leukocytes in response to acute resistance exercise stress will contribute to our understanding of the intricate communication between cytokines and immune cells in muscle-repair models. It will also provide insight regarding other acute stressors and immune challenges for which immune cell responses are mediated by cytokines and hormonal signals.
The purpose of the present study was to investigate the efficacy of acute HMB-FA supplementation alone and in conjunction with CWI on circulating TNF-␣ levels, as well as its receptor expression on immune cells in response to exerciseinduced muscle damage. We hypothesized that HMB-FA and a CWI combination would blunt receptor expression of TNF-␣ on circulating monocytes following exercise-induced muscle damage and subsequent bouts of exercise to a higher degree than with either modality alone.
METHODS
Participants. Forty resistance-trained men (22.3 Ϯ 2.4 yr, 1.75 Ϯ 0.05 m, 83.0 Ϯ 8.3 kg) volunteered to participate in this study. Participants were divided randomly into one of four groups: ingestion of HMB-FA, ingestion of placebo (PL), ingestion of HMB-FA and CWI (HMB-FA-CWI), and ingestion of PL and CWI. Following an explanation of all procedures, risks, and benefits, each participant gave his informed consent before participation in this study. The Institutional Review Board for the protection of human participants of the university approved the research protocol. For inclusion in the study, participants had to have a minimum of 1 yr of resistancetraining experience, particularly in the squat exercise. Participants were not permitted to use any additional nutritional supplements or medications while enrolled in the study. Screening for nutritional and hormonal supplements was accomplished via a health-history questionnaire, completed during participant recruitment. Participants were not permitted to partake in any personal recovery strategies while enrolled in the study, including baths, saunas, stretching routines, foam rollers, or massage.
Study protocol. The investigation was performed as a PL-controlled, double-blind, randomized design. Participants reported to the Human Performance Laboratory (HPL) on four separate occasions. On the first visit (T1), participants were tested for maximal strength [one repetition maximum (1-RM)] on the barbell back squat, dead lift, and barbell split-squat exercises. Before the second visit (T2), participants were instructed to refrain from exercise for a minimum of 72 h prior. Also, before subsequent exercise sessions (T3, T4), participants were instructed to report to the HPL in a 10-h fasted state. During T2, participants performed a lower-body resistance exercise session that consisted of four sets of the squat, dead lift, and barbell split-squat exercises. The squat exercise was performed with 80% of the participant's previously measured 1-RM, and the dead lift and barbell split-squat exercises were performed with 70% of the participant's previously measured 1-RM. The rest interval between each set and between exercises was 90 s. Participants were encouraged to perform as many repetitions as possible, up to 10 repetitions for each set. Participants then reported back to the HPL, 24 (T3) and 48 h (T4) postexercise (24P and 48P, respectively). During T3 and T4, participants performed four sets of as many repetitions as possible (up to 10 repetitions/set) of the squat exercise using the same load as that used during T2, with 90 s of rest given between each set.
HMB-FA supplementation. The HMB-FA supplement was in gel form and consisted of 1 g/serving. The HMB-FA was obtained from Metabolic Technologies (Ames, IA). During T2, one serving of HMB-FA or PL was consumed 30 min before the exercise session, 2 h following the exercise session, and 6 h following the exercise session. During T3, participants consumed one serving of the HMB-FA or PL, 30 min before the exercise session, 2 h following the exercise session, and 6 h following the exercise session. During T4, participants consumed one serving of the HMB or PL, 30 min before the exercise session only. All HMB-FA and PL ingestion took place in the HPL and/or was witnessed by a study researcher.
Cold-water immersion. The participants in the HMB-FA-CWI and CWI groups were immerged in an ice bath along with the supplement or PL intervention. The ice bath was set to 22.9-cm high with ice water at 10 -12°C immediately following postexercise blood draw and ultrasound (T2) or immediately postexercise (IP; T3). Participants were required to emerge their lower body fully into the water up to their umbilicus for 10 min. Those who were not in the CWI groups were required to remain in the HPL for an additional 20 min postexercise to ensure a similar postexercise resting period.
Anthropometric measurements. Before maximal strength testing, anthropometric measurements, including height, body mass, and body-fat percentage, were conducted. Body mass (Ϯ0.1 kg) and height (Ϯ0.1 cm) were measured using a patient weighing scale (Health o meter Professional, Model 500KL; Pelstar, McCook, IL). All body-composition measures were performed using standardized procedures described previously for collecting skinfold measurement from the triceps, suprailiac, abdomen, and thigh (19) and formulas published previously for calculating body-fat percentage (24) . All measurements of skinfold were performed by the same researcher using the same pair of skinfold calipers (Caliper Skinfold Baseline, Model #MDSP121110; Medline, Mundelein, IL).
Maximal strength testing. Each participant performed a standardized warm-up consisting of 5 min on a cycle ergometer, 10 body wt squats, 10 walking lunges, 10 dynamic walking hamstring stretches, and 10 dynamic walking quadriceps stretches. The 1-RM tests were performed using methods described previously (19) . Each participant performed a warm-up set using a resistance that was approximately 40 -60% of his perceived maximum and then performed three to four subsequent trials to determine the 1-RM. A 3-to 5-min rest period was provided between each trial. The squat exercise required the participants to place an Olympic bar across the trapezius muscle at a self-selected location. Each participant descended to the parallel position, which was attained when the greater trochanter of the femur reached the same level as the knee. The participant then ascended until full knee extension. The dead-lift exercise required the participant to grasp an Olympic bar slightly wider than shoulder width with the arms in a fully extended position. A closed, open, or alternating hand grip was allowed and kept consistent for each participant. From a flexed position, the participant extended his hips and knees until the body assumed an erect standing position. The barbell split-squat 1-RM was assessed using a prediction formula based on the number of repetitions performed to fatigue using a given weight (4). The barbell split squat required the participant to place an Olympic bar across the trapezius muscle at a self-selected location. The participant assumed an alternating leg stance with the dominant leg forward. For each repetition, the participant flexed the dominant knee until it was over the dominant foot. The trailing knee was lowered to the floor without making contact, while the torso remained erect. The participant pushed off with both legs to return back to the starting position. Trials not meeting the range of motion criteria for each exercise were discarded.
Subjective measures of soreness and pain. Subjective feelings of leg soreness and leg pain were assessed using a 15-cm visual analog scale (VAS). The scale was anchored by the words "Lowest" and "Highest" to represent extreme ratings where the greater-measured value represented the greater feeling. Questions were structured as "My level of leg soreness is: . . ." and "My level of leg pain is: . . . ." The VAS was assessed on T2 before exercise (PRE) and before HMB or PL ingestion, IP, and 30 min postexercise (30P). The VAS was assessed on T3 and T4, PRE and before HMB-FA or PL ingestion. The validity and reliability of VAS in assessing fatigue and energy were established previously (29) .
Blood measurements. During the T2 experimental session, blood samples were obtained PRE, IP, and 30P. During the T3 and T4 experimental sessions, blood samples were obtained PRE and marking 24P and 48P. During T2, all blood samples were obtained using a 20-gauge Teflon cannula placed in a superficial forearm vein using a three-way stopcock with a male luer-lock adapter. The cannula was maintained patent using an isotonic saline solution. PRE blood samples were drawn following a 15-min equilibration period before exercise. IP blood samples were taken within 1 min of exercise cessation. Following the resistance-exercise protocol, participants remained in the supine position for the full 30-min recovery phase before the 30P blood sample being drawn, except for the participants in the CWI groups, who spent the first 10 min of the 30 min in the ice bath. All T2 blood samples were drawn with a plastic syringe, while the participant was in a supine position. During T3 and T4, only PRE blood samples were drawn (24P and 48P, respectively). These blood samples were obtained from an antecubital arm vein using a 20-gauge disposable needle equipped with a Vacutainer tube holder (Becton Dickinson, Franklin Lakes, NJ) with the participant in a supine position for at least 15 min. Each participant's blood samples were obtained at the same time of day during each session.
Blood samples were collected into two Vacutainer tubes-one containing no anticoagulant and the second containing K 2EDTA. A small aliquot of whole blood was removed from the K2EDTA tube and used for determination of hematocrit and hemoglobin. The blood in the serum tube was allowed to clot at room temperature for 30 min and subsequently centrifuged at 3,000 g for 15 min, along with the remaining whole blood from the K 2EDTA plasma tube. The resulting plasma and serum were aliquoted into separate 1.6-ml microcentrifuge tubes and frozen at Ϫ80°C for later analysis.
Biochemical analysis. Plasma HMB was analyzed by Metabolic Technologies by GC-MS with methods outlined previously (33) . CK was analyzed by enzymatic assay (Sekisui Diagnostics, Charlottetown, Prince Edward Island, Canada), and absorbance was read on a spectrophotometer (Eon; BioTek, Winooski, VT). Myoglobin concentration was determined via a myoglobin ELISA kit (Cat no: MG017C; Calbiotech, Spring Valley, CA) and prepared per the manufacturer's instructions. Determination of serum immunoreactivity values was established using a BioTek Eon spectrophotometer. To eliminate interassay variance, all samples for a particular assay were thawed once and analyzed in the same assay run by a single technician. All samples were run in duplicate with a mean intra-assay variance of 2.6% for CK and 5.73% for myoglobin.
Hemoglobin was analyzed in triplicate from whole blood using an automatic analyzer (HemoCue, Cypress, CA). Hematocrit was analyzed in triplicate from whole blood via microcentrifugation (CritSpin; StatSpin, Iris Sample Processing, Westwood, MA) and microcapillary technique. Coefficients of variation for each assay were 3.73% for hemoglobin and 0.65% for hematocrit.
Serum samples were assayed for concentrations of TNF-␣, using a multiplex cytokine assay (Milliplex, Cat no. HCYTOMAG-60K; Millipore, Billerica, MA) on a MAGPIX instrument (Luminex, Austin, TX), according to the manufacturer's instructions. All samples were run in duplicate with a mean intra-assay variance of 8.36% for TNF-␣.
Cell staining. K 2EDTA-treated peripheral whole blood was used to identify monocytes and quantify the TNFR1 expression by direct immunofluorescence and flow cytometry. Erythrocytes were first lysed from 350 l of K2EDTA-treated whole blood with BD Pharm Lyse solution (BD Biosciences, San Jose, CA) within 30 min of collection. Samples were then washed three times by centrifugation and aspiration in staining buffer containing 1ϫ PBS and FBS. Leukocytes were then resuspended in 100 l BD PharMingen stain buffer (BD Biosciences). Direct staining methods were used to label CD14 and CD120a. FITC conjugated to anti-CD120a (H398, IgG2␣; AbD Serotec, Raleigh, NC) and peridinin chlorophyll protein (PerCP)-Cy5.5-conjugated anti-CD14 (M5E2; BD PharMingen, BD Biosciences) were used in the receptor-labeling process. Surface staining was performed by adding 10 l directly conjugated FITC antiCD120a and 5 l directly conjugated PerCP-Cy5.5 anti-CD14 to the cell suspension and incubating in the dark for 30 min at 20°C. Cells were resuspended in 1.0 ml stain buffer for flow cytometry analysis.
Flow cytometry. Flow cytometry analysis of stained cells was performed on a BD Accuri C6 flow cytometer (BD Biosciences), equipped with BD Accuri analysis software (BD Biosciences). Forward-and side-scatter, along with four fluorescent channels of data, were collected using two lasers, providing excitation at 488 nm and 640 nm. Monocytes were determined by initial gating based on forward-and side-scatter, followed by gating for CD14ϩ cells, as described previously (50) . Dead cells and debris were excluded by forward-and side-scatter gating. A minimum of 10,000 events, defined as CD14ϩ monocytes, was obtained with each sample.
Analysis of monocyte subpopulations was completed by quadrant analyses, in which CD14 was compared with CD120a. Mean fluorescence of CD120a on CD14ϩ cells was recorded, representing the mean density of TNFR1/cell (13) . To control for fluorescence spillover, correction subtraction values were applied when necessary, per the manufacturer's instructions (BD Biosciences).
Dietary recall. Participants were instructed to record as accurately as possible everything they consumed during the day after the exercise protocol on T2 and after the exercise protocol on T3. Participants were instructed not to eat within 10 h of reporting to the HPL for subsequent visits. FoodWorks Dietary Analysis software (McGraw-Hill, New York, NY) was used to analyze the dietary recalls for total kilocalorie intake and macronutrient distributions (carbohydrate, protein, and fat).
Statistical analysis. Two separate two-way ANOVAs [time (PRE, IP, 30P, 24P, 48P) ϫ group (HMB-FA, HMB-FA-CWI, CWI, PL)] were used to analyze TNF-␣ and TNFR1 data. When appropriate, follow-up analyses included one-way repeated-measures ANOVAs and Tukey post hoc comparisons. An ␣-level of P Ͻ 0.05 was considered statistically significant for all comparisons. Before analysis, all data were assessed to ensure normal distribution, homogeneity of variance, and sphericity. If assumption of sphericity were violated, a Greenhouse-Geisser correction was applied. Differences in dietary composition among all four groups were analyzed using a one-way ANOVA. Results were considered significant at an ␣-level of P Յ 0.05. All data are reported as mean Ϯ SD.
To make inferences on true effects of the different treatment modalities on recovery performance, an analysis based on the magnitude of differences, calculated from 90% confidence intervals, as described previously by Batterham and Hopkins (2) , was used in this study. Differences between PRE and all subsequent time points were calculated for each treatment group (PL, HMB-FA, HMB-FA-CWI, CWI). Additionally, differences at each time point among the four treatments were calculated. These change scores were then analyzed via a published spreadsheet (22) , with the smallest, nontrivial change set at 20% of the grand SD (2) . All data are expressed as a mean effect Ϯ SD, with percent chances of a beneficial, trivial, or negative outcome. Qualitative inferences, based on quantitative chances, were assessed as: Ͻ1%, almost certainly not; 1-5%, very unlikely; 5-25%, unlikely; 25-75%, possibly; 75-95%, likely; 95-99%, very likely; and Ͼ99%, almost certainly (23) .
In addition, percent-change scores were calculated for each participant from PRE to IP, PRE to 30P, PRE to 24P, and PRE to 48P. These percent-change scores were averaged separately for the HMB-FA and PL groups, and 95% confidence intervals were constructed around the mean percent-change scores (Fig. 1) . When the 95% confidence interval includes 0, the mean percent-change score is no different from 0, which can be interpreted as no statistical change (P Ͼ 0.05). However, if the 95% confidence interval does not include 0, the mean percent change for that variable can be considered statistically significant (P Յ 0.05) (9) .
RESULTS
There were no significant differences among groups in any of the physical characteristics. The average of resistancetraining experience of the participants was 6.1 Ϯ 3.1 yr, and the average 1-RM squat was 146.3 Ϯ 28.9 kg for all participants. The training volume performed of the squat exercise (number of repetitions ϫ load) was similar for all four groups during each training session. Significant differences were noted in the training volume from T2 to T3, as well as from T2 to T4. The muscle-damaging protocol at T2 resulted in significant elevations in subjective feelings of muscle soreness and pain where soreness increased from 0.5-1.0 cm at T2 to 7.7-12.7 cm at T2-T3. Muscle soreness corresponded with significant elevations in CK from PRE (103.4 -173.4 U/l), 24P (292%; 468.9 -638.5 U/l), and 48P (276%; 424.6 -609.5 U/l) post-T2 and myoglobin from PRE (18.3-35.5 ng/ml) to IP (225%; 63.8 -114.8 ng/ml) and 30P (418%; 89.3-180.6 ng/ml). CK and myoglobin levels did not appear to be affected by HMB-FA; however, these data will be reported as part of a separate investigation. Dietary recall analysis revealed no differences in total caloric or protein intake (g and g/kg body mass) among groups on days of T2 and T3.
Plasma kinetics of HMB. Plasma HMB values are depicted in Fig. 2 . Plasma HMB was elevated significantly (P Ͻ 0.001) in HMB-FA and HMB-FA-CWI groups at all time points compared with PL and CWI. There was a significant time effect for plasma HMB-FA pairwise comparisons showing differences among PRE values and IP (P ϭ 0.003), 30P (P ϭ 0.003), and 48P (P ϭ 0.038). However, there was no significant elevation in plasma HMB-FA levels when comparing PRE with 24P in the HMB-FA group (P Ͼ 0.05). HMB-FA-CWI was elevated in relation to PRE levels only at IP (P Ͻ 0.001) and 30P (P ϭ 0.001), whereas no significant differences were seen at 24P (P ϭ 0.089) and 48P (P ϭ 0.522).
Circulating TNF-␣ responses to exercise. The two-way time (PRE, IP, 30P, 24P, 48P) ϫ group (HMB-FA, HMB-FA-CWI, CWI, PL) for TNF-␣ indicated a significant time effect (P ϭ 0.030) but no significant main effects for group (P Ͼ 0.05) or time ϫ group interactions. Pairwise comparisons showed that circulating TNF-␣ at 48P was significantly lower than IP (P ϭ 0.013) and 30P (P ϭ 0.001) in all groups. When follow-up one-way repeated measures were analyzed for each group, only PL (P ϭ 0.006) and CWI (P ϭ 0.045) were elevated significantly at IP from PRE. In addition, at 24P and 48P, TNF-␣ in PL was significantly lower (p Յ 0.05) than IP values. CWI was significantly lower (P ϭ 0.011) at 48P compared with IP values.
Magnitude-based inferences comparing treatment groups can be observed in Table 1 . Results suggest that TNF-␣ levels in the HMB-FA group were "Likely Decreased" from PRE to IP, with a mean effect of Ϫ2.9 Ϯ 3 compared with PL, and Likely Decreased compared with CWI, with a mean effect of Ϫ2.5 Ϯ 3.3 pg/ml (Table 2 ). In addition, HMB-FA-CWI was Likely Decreased compared with CWI between PRE and IP, with a mean effect of Ϫ3.3 Ϯ 4.1. TNF-␣ changes for CWI were "Likely Increased" compared with the HMB-CWI group between PRE and 30P, with a mean effect of 2.5 Ϯ 2.7 pg/ml. The HMB-FA-CWI group was Likely Decreased compared with PL, with a mean effect of Ϫ2.4 Ϯ 2.8 pg/ml. Inferential analyses between PRE and 24P were "Unclear" for comparisons in all groups. At PRE-48P, CWI was "Possibly Increased," with a mean effect of 0.69 Ϯ 1.2 pg/ml. All other comparisons were interpreted as Unclear.
The mean percent scores on circulating TNF-␣ indicated that all groups responded similarly from PRE to 30P, PRE to 24P, and PRE to 48P (see Fig. 4 ). However, the percent increases in TNF-␣ levels from PRE to IP were elevated significantly for both PL and CWI groups (P Ͻ 0.05), whereas the percent change for HMB-FA and HMB-FA-CWI did not reach significance (P Ͼ 0.05).
TNFR1 density on monocytes-CD120ϩ/CD14ϩ. Gating characteristics for TNFR1 are represented in Fig. 3 . The two-way [time (PRE, IP, 30P, 24P, 48P) ϫ group (HMB-FA, HMB-FA-CWI, CWI, PL)] for TNFR1 density (expressed as relative fluorescence) indicated a significant time effect (P ϭ 0.003) but no main effects for group (P Ͼ 0.05) and no significant time ϫ group interactions. In addition, a one-way repeated-measures ANOVA showed a significant effect of time with a significant increase in TNFR1 expression at 30P for the PL (P ϭ 0.023) and CWI (P ϭ 0.020) groups, whereas no other groups were elevated significantly at 30P. Magnitude-based inferences suggest a "Likely Decrease" in the change of relative florescence from PRE to 30P in the HMB group compared with PL and CWI, with a mean effect of Ϫ5,700 Ϯ 6,100 and Ϫ6,600 Ϯ 6,500 relative fluorescence units (RFU), respectively ( Table 2) . Comparisons between PRE and 24P indicated that CD120aϩ/CD14ϩ TNFR1 expression for CWI was Likely Increased compared with HMB-FA-CWI, with a mean effect of 4,800 Ϯ 5,300 RFU. Magnitudebased inferences show that CD120aϩ/CD14ϩ TNFR1 expression between PRE and 48P was "Very Likely Increased" for CWI compared with the HMB-FA-CWI group, with a mean effect of 6,400 Ϯ 4,500 RFU, and the HMB-FA-CWI was Likely Decreased compared with the PL group, with a mean effect of Ϫ6,200 Ϯ 7,800 RFU.
The mean percent scores for TNFR1 expression indicated that all groups responded similarly from PRE to IP, PRE to 24P, and PRE to 48 (Fig. 4) . However, the percent increases in TNFR1 [expressed as relative fluorescence (receptor density)] from PRE to 30P were elevated significantly for both PL and CWI groups (P Ͻ 0.05), whereas percent change for HMB-FA and HMB-FA-CWI did not reach significance (P Ͼ 0.05).
DISCUSSION
The main findings of this investigation were that circulating TNF-␣ and TNFR1 expression on monocytes was elevated in response to heavy resistance exercise and during subsequent recovery. Furthermore, HMB-FA supplementation appears to attenuate elevations in circulating TNF-␣ immediately following an acute heavy resistance exercise bout and appears to reduce TNFR1 expression on human monocytes at 30P compared with PL and CWI groups. CWI therapy alone did not attenuate the increase in circulating TNF-␣ or TNFR1 expression postexercise or during recovery. In addition, the combination of CWI and HMB ingestion did not provide any additive benefits.
Circulating TNF-␣ significantly increased in response to a lower-body, muscle-damaging resistance exercise protocol in resistance-trained men. Our results contrast with previous research that reports only a slight increase or no increase in circulating TNF-␣ following differing exercise protocols (3, 18, 46, 52) . However, our study differs from prior research, as we recruited resistance-trained men and implemented a higher volume resistance-exercise protocol, eliciting both eccentric and concentric muscle contractions. In contrast, previous studies used eccentric exercise protocols in untrained participants (3, 18) . Hence, it may be that compared with prior studies, the larger exercise volume completed by trained men resulted in a relatively greater circulating TNF-␣ response. Additionally, due to the training experience of our participants, the higher volume of dynamic resistance exercise completed in our study may have contributed to the increased TNF-␣ response. The observed elevation in circulating TNF-␣ was likely indicative of the acute inflammatory response, due to the high amount of muscle damage that occurred in our study (49) . The acute exercise protocol resulted in significant muscle damage, as quantified by circulating CK and myoglobin, which was within the range of muscle-damaging protocols reported previously (20, 21, 58) . CK levels did not appear to be affected by HMB-FA supplementation, as reported in a separate investigation. However, it is important to consider that in vitro mechanisms of TNF-␣ signaling pathways may differ from those found in vivo (28) . In animal models, TNF-␣ appears to impair protein synthesis by delaying or inhibiting translation initiation, thus decreasing mRNA translational efficiency (28) .
Whereas previous studies have evaluated the circulating TNF-␣ response to various exercise protocols, this is the first investigation to measure TNF-␣ responses to muscle-damaging exercise accompanied with HMB-FA supplementation. HMB-FA attenuated the rise in circulating TNF-␣ levels at IP compared with PL Likely Decreased *Mean effect refers to the first named group minus second named; †90% CI: add and subtract this number to the mean effect to obtain the 90% CIs for the true difference. Interpretation represents the likelihood that the true value will have the observed magnitude. TNFR1, TNF-␣ receptor 1. and CWI. This finding is consistent with mechanisms proposed by Eley et al. (13), where a potential pathway, in which HMB attenuates muscle-protein breakdown, is by inhibiting the effects of TNF-␣ and its signaling for production of reactive oxygen species. Additionally, Nunes et al. (34) found HMB treatment to decrease the production of TNF-␣ from isolated peripheral blood mononuclear cells. Since TNF-␣ is known to promote additional muscle breakdown, attenuation of circulating TNF-␣, immediately following exercise, may blunt further inflammation cascades, which may result in attenuated muscle damage (31) . HMB has also been shown to mitigate inhibition of muscle-protein synthesis by upregulation of the mammalian target of rapamycin pathway (12) . In our study, whereas there were no significant differences in PRE TNF-␣ concentration among groups (P ϭ 0.368), both HMB-FA-treated groups (HMB-FA, HMB-FA-CWI) were elevated (63.9%) PRE compared with PL and CWI. Since the supplement was administered ϳ15 min before the PRE blood draw, and plasma HMB was elevated at PRE in supplementtreated groups, it is possible that HMB-FA causes a rise in TNF-␣ serum concentration soon after ingestion, although we did not measure before supplement administration. HMB-FA has been reported by Fuller et al. (16) to peak in the plasma at ϳ36 min postingestion; however, significant increases in plasma HMB were observed only 5 min after administration. Similarly, the plasma kinetics of HMB-FA and HMB-FA-CWI groups in the present study are consistent with the findings of Fuller and colleagues (16) , who observed peak HMB plasma levels at 30P. It is important to mention that our 30P time point is actually ϳ60 min after HMB-FA administration. So, whereas the 30P value may not represent the peak plasma concentration in our participants, it is still consistent with previous work (16) . Additionally, evidence supports postprandial elevations in cytokine production, based on nutritional composition (5). Therefore, it is possible that HMB-FA ingestion evokes an early elevation in cytokine production, specifically TNF-␣. However, as we did not anticipate this finding, we did not measure TNF-␣ before initial HMB-FA ingestion to evaluate this potential early elevation. Nevertheless, it is plausible that the potential early elevation in circulating TNF-␣ in the HMB-FA group was the reason for the attenuated change from PRE to IP. Since this is currently not known, follow-up studies are needed to evaluate the time course of cytokine responses to HMB-FA ingestion without the exercise stress to determine the nature of this potential effect. Furthermore, the HMB-FA group experienced a greater elevation in plasma HMB than the HMB-FA-CWI group, most notably at 48P. Whereas not statistically significant, participants in the HMB-FA (81.1 kg) were smaller, on average, than the HMB-FA-CWI (87.6 kg); thus it may be more appropriate to dose HMB-FA relative to body weight.
CWI alone did not prevent a rise in TNF-␣ concentrations or TNFR1 expression postexercise or during recovery. These findings agree with a previous investigation that reports no effect of CWI following eccentric exercise on circulating TNF-␣ concentrations (53) . A recent study examining topical cooling on eccentric elbow flexor muscle damage found significantly reduced TNF-␣ levels 24P, but no change from baseline was observed at any other time points (53) . Therefore, it is possible that the TNF-␣ response to exercise varies with the amount of muscle mass involved, where exercises involving more musculature produce an augmented cytokine response. It is also important to note that the topical cooling study used female participants, since immune response differences have been observed between men and women (15) . It is also possible that cold therapy may be more successful in slowing hemodynamics, thus reducing or delaying the cytokine response.
TNFR1 expression on monocytes, in response to resistance training, has not been researched previously. We hypothesized originally that the TNFR1 may reveal insights as to how HMB-FA treatment may attenuate the protein degradation pathways. In this study, expression of TNFR1 was Likely Decreased in the HMB-FA group compared with both PL and CWI groups. In addition, when these data were examined by mean percent changes, only PL and CWI were elevated significantly at 30P. TNFR1 was not elevated significantly in HMB-FA and HMB-FA-CWI. This suggests that HMB-FA supplementation may have blunted the elevation of TNFR1 expression observed in the PL and CWI groups. Previous research has shown that HMB may attenuate muscle-protein breakdown by blocking the effects of TNF-␣ (12, 13). Whereas we observed an increase in TNFR1 expression on monocytes following exercise, others have previously disqualified monocytes as the source of increased circulating TNF-␣ levels following exercise (47, 48) . This may explain why we did not observe an accompanying increase in circulating TNF-␣, even though receptor expression on monocytes was elevated in PL and CWI groups at 30P. However, with the consideration that monocytes are known to infiltrate damaged muscle and subsequently continue neutrophil-initiated muscle damage through differentiation into macrophages (36) , it is plausible that monocytes with an elevated expression of TNFR1 will generate subsequent TNF-␣-producing macrophages that elicit more damage. Hence, the attenuated elevation in expression in TNFR1 with HMB-FA supplementation may explain the mechanisms to how HMB attenuates protein synthesis. Our results reveal that it may occur through attenuating the TNFR1 expression on monocytes that initiate the inflammatory cascade responsible for muscle damage and repair. Since the highest concentration of macrophages in damaged tissue occurs ϳ24P (44), it is logical that no further elevations in TNFR1 expression were observed after 30P, as the TNFR1-presenting mono- cytes have likely infiltrated the damaged muscle site. However, further work is needed to understand the time course of TNFR1 expression in muscle recovery with accompanying muscle biopsies to determine the relationship between TNFR1-expressing monocytes and intramuscular macrophage action. Whereas this is the first study to report the effects of HMB-FA on circulating TNF-␣ and TNFR1 expression following heavy resistance exercise, several considerations should be noted in the interpretation of the results. The first consideration involves the dosage of HMB. Whereas most prior studies involving HMB used a 3-g/day split over three doses during the day (10, 33, 35, 56) , a recent study (57) found that a bolus of HMB (3.42 g) was also successful in reducing muscle-protein breakdown, while promoting muscle-protein synthesis. In addition, Wilson et al. (58) found a 3-g bolus of HMB-Ca to significantly attenuate indices of muscle damage when taken before exercise (58) . It is possible that the effects of HMB on the immune response to exercise may be dose dependent, and larger amounts of HMB or a preceding loading phase, as implemented in previous literature (25, 35, 39, 41, 51, 56) , would produce a more profound immune response. In addition, it is clear that HMB has a lesser effect on individuals with more resistance-training experience (20, 26, 27, 45) . Furthermore, healthy, trained humans express different immune profiles than their untrained or sedentary counterparts (6) . Hence, results should be interpreted in the context of the population examined. Further studies are needed in sedentary individuals, women, older adults, or other populations.
An additional, important consideration for the interpretation of our findings is the complicated nature of the connection between inflammatory processes and muscle damage. In the context of this investigation, we sought to mimic situations in which athletes are required to compete multiple times with little recovery time in between exercise bouts. Since the initial immune response following muscle-damaging exercise is associated with subsequent declines in muscular contractile performance, pain, and other determents, the conventional approach to treatment has been to attempt to prevent inflammation (32) . However, although inflammation can cause further injury to muscle, the attenuation of initial inflammation may actually impair recovery in some situations (54) . Both pro-and anti-inflammatory cytokines are believed to be necessary for the repair and regeneration of skeletal muscle morphology and function (36) . In a recent comprehensive study of cytokine responses following an elite soccer game, parallel increases in both pro-and anti-inflammatory cytokines were observed and considered characteristic of normal exercise adaptations (1). However, as described in a recent review by Urso (54) , the time points in the inflammatory cascade, where pro-inflammatory and antiinflammatory actions are beneficial or detrimental to recovery, are yet to be elucidated. Thus it may be possible that an attenuated inflammatory response may actually blunt or delay subsequent muscle repair. Nevertheless, further studies are needed that chart the time course and magnitude of repair in response to interventions where the inflammatory cascade is disrupted to evaluate this possibility.
Additionally, whereas the present study examined TNF-␣ and its receptor as a possible mechanism to explain responses to HMB supplementation, it is important to acknowledge that several additional cytokines (i.e., IL-1, IL-6) are involved in the inflammatory response that may impact the actions of TNF-␣. Whereas HMB-FA appears to attenuate the TNF-␣ response, it is also possible that other pro-or anti-inflammatory cytokines may be attenuated directly or as a downstream response to the TNF-␣ attenuation. Future studies are needed to evaluate multiple simultaneous cytokine-marker responses to provide a broader picture of cytokine actions in inflammatory responses.
In conclusion, HMB-FA supplementation in healthy, resistance-trained men attenuated circulating TNF-␣ and TNFR1 expression on human monocytes immediately following heavy resistance exercise. Findings reveal a potential blunted or delayed inflammatory response following resistance training with HMB-FA supplementation. Furthermore, it appears that CWI treatment has no effect on plasma TNF-␣ measures and TNFR1 expression on monocytes. These findings provide essential information in an attempt to fully understand the effect that resistance training has on immune cell responses and add to our knowledge of mechanisms of cytokine-induced inflammation and muscle repair. Furthermore, our results provide information on a nutritional intervention that may blunt these processes, providing potential applications to clinical scenarios of muscle repair.
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